Please try another search
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company’s diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Name | Age | Since | Title |
---|---|---|---|
Shu Kam Mok | 64 | - | Member of Scientific & Medical Advisory Board |
Pasi Antero Janne | - | - | Member of Scientific & Medical Advisory Board |
George K. Gittes | - | 2020 | Member of Scientific Advisory Board |
George Simon | - | - | Member of Scientific & Medical Advisory Board |
James E. Rothman | 73 | 2012 | Strategic Advisor to the Board of Directors |
George E. Peoples | - | 2021 | Member of Clinical Advisory Board |
Michael Morse | - | 2021 | Member of Clinical Advisory Board |
William R. Wilson | 74 | 2020 | Independent Director |
Andrew B. Becker | - | 2021 | Member of Clinical Advisory Board |
Jose Antonio Moreno Toscano | 51 | 2020 | Independent Non-Executive Chairman |
Ryan M. Confer | 42 | 2016 | President, CEO, CFO & Director |
Jack A. Roth | - | - | Chairman of Scientific & Medical Advisory Board |
Brent M. Longnecker | 68 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review